Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Receivables (2016 - 2026)

Intellia Therapeutics has reported Receivables over the past 12 years, most recently at $9.1 million for Q1 2026.

  • Quarterly Receivables fell 13.37% to $9.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Mar 2026, down 13.37% year-over-year, with the annual reading at $9.5 million for FY2025, 31.94% up from the prior year.
  • Receivables was $9.1 million for Q1 2026 at Intellia Therapeutics, down from $9.5 million in the prior quarter.
  • Over five years, Receivables peaked at $37.5 million in Q4 2023 and troughed at $1.2 million in Q3 2023.
  • The 5-year median for Receivables is $9.0 million (2024), against an average of $11.4 million.
  • Year-over-year, Receivables crashed 85.04% in 2023 and then skyrocketed 637.83% in 2024.
  • A 5-year view of Receivables shows it stood at $5.4 million in 2022, then skyrocketed by 597.76% to $37.5 million in 2023, then crashed by 77.26% to $8.5 million in 2024, then rose by 11.54% to $9.5 million in 2025, then dropped by 4.21% to $9.1 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Receivables are $9.1 million (Q1 2026), $9.5 million (Q4 2025), and $11.0 million (Q3 2025).